AKT1 and esophageal cancer: Our in vitro and in vivo results showed that specific inhibitors of PI3K/AKT inhibited proliferation and promoted apoptosis of esophageal cancer cells in a dose-dependent manner (Figures 2-5), thus indicating the therapeutic potential of targeting PI3K/AKT in esophageal cancer treatment.